Abstract Body

Background: Targeted measurement of over 400 plasma lipid species by mass spectrometry can sensitively identify changes in the plasma lipidome associated with the development of atherosclerosis and stratify patients into levels of future cardiovascular risk. Some of the HIV and ART-associated cardiovascular risk that persists despite correction for fasting lipids may be explained by changes in plasma lipidome. This study was performed to determine the change in lipidome associated with initiation of different antiretroviral regimens. Methodology: Plasma lipid profiling (by liquid chromatography, electrospray isonisation-tandem mass spectrometry) was performed on 297 samples from the ALTAIR study which randomised ART-naive HIV positive participants to one of three initial regiments, enofovir/emtricitabine with efavirenz (EFV), ritonavir-boosted atazanavir (ATZr) or zidovudine/abacavir (ZDV/ABC). Participants (n = 99) who remained on the randomised regimen with complete samples available at baseline, week 12 and 48 were included. 306 lipid species were detected in significant abundance for inclusion. Results: Baseline characteristics and lipid profile (including lipid classes and species) were similar between the arms. Lower total and LDL cholesterol was seen with ZDV/ABC at week 48 compared with EFV or ATZ/r. In the EFV and ATZr arms there were significant changes in a number of lipid species from baseline to week 48 (27 and 49 respectively), some of which (4 and 6 respectively) have been previously identified to be associated with cardiovascular events in HIV. There were no significant changes from baseline seen with ZDV/ABC. At week 48 significant differences in lipid species and classes by treatment regimen were detected; including increased trihexosylceramide (1.24 nM vs 1.0 nM, p <0.001), monohexosylceramide (9.81 nM vs 6.80 nM, p<0.001) and GM3 ganglioside (4.43 nM vs 3.20 nM, p<0.001) classes with EFV compared with ATZr. The same pattern of results was seen when comparing EFV with ZDV/ ABC. The total and percent change in lipid species from baseline to week 48 was not statistically different between arms. Baseline HIV and metabolic characteristics did not predict changes in lipid species. Early change in HIV viral load was predictive of change in 24 lipid species and 1 class at 12 weeks; independent of treatment arm. Conclusions: ART with EFV or ATVr induces significant changes in plasma lipidome which may be associated with future cardiovascular risk.